O-RAN-ALLIANCE-E.V.
Memorandum of Understanding between O-RAN ALLIANCE and OpenAirInterface Software Alliance (OAI)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005917/en/
In recently signed Memorandum of Understanding, OAI and O-RAN ALLIANCE agreed to co-operate on open Radio Access Network issues, open source software development, and 5G as well as next generation platforms for demonstrating O-RAN technology. Both organizations will encourage sharing of information in areas of mutual interest and may hold joint meetings and workshops.
”I am very pleased to see the excellent cooperation between O-RAN and OAI,” said Alex Jinsung Choi, Chair of the Board of O-RAN ALLIANCE and SVP Group Technology, Deutsche Telekom. “The MoU will strengthen our cooperation in development of open source software for the RAN. It will allow a more focused cooperation between both organizations and will enhance our software development.”
“We are very excited at the signing of this MoU,” said Raymond Knopp, President of the OpenAirInterface Software Alliance. “This has been a long standing goal for the OpenAirInterface Software Alliance. Firstly, the OAI software follows the O-RAN architecture and paves the way for showcasing the next generation cellular wireless technologies. Secondly, the two organizations are very complementary in their value propositions. We look forward to capitalizing on this collaboration in the future.”
Two New Open Testing and Integration Centres (OTIC) Approved in Asia & Pacific
O-RAN ALLIANCE announces that Asia & Pacific OTIC by ritt7layers and Asia & Pacific OTIC in Singapore have joined the community of Open Testing and Integration Centres. With this addition there are now 11 approved OTICs across Europe, the Americas, and Asia.
OTICs are vendor-independent, open, and qualified labs approved by the O-RAN ALLIANCE that issue awards in the O-RAN Certification and Badging Program.
For more information about OTICs and O-RAN ALLIANCE’s testing and integration work please visit our website.
O-RAN Release 3 Implements Features with 58 New or Updated Technical Documents
O-RAN Release 003 includes enhancements to RAN Slicing and SMO features. It also introduces new features:
- Security requirements and countermeasures for RAN Intelligent Controller (RIC) interfaces and apps, O-Cloud and O2 interface
- Security technical reports with threat and risk analysis outputs for application lifecycle management, log management, service management and orchestration, shared O-RU
- RIC-enabled massive MIMO optimization for non-Grid of Beams (GoB) beamforming method
- RAN Analytics Information Exposure (RAIE) use cases and RIC architecture enhancements for extending RAN-aware optimization capabilities to external services and applications
O-RAN Release 003 also includes 10 new specification titles:
- Network Energy Savings Use Cases Technical Report
- Decoupled SMO Architecture Technical Report
- Application Protocols for R1 Services
- O1 Interface Specification for Near-RT RIC
- Near-RT RIC APIs specification
- Requirements and Reference Design Specification for Enterprise Microcell
- Study on Security for Application Lifecycle Management
- Study on Security Log Management
- Study on Security for Service Management and Orchestration (SMO)
- Study on Security for Shared O-RU
For more details about newly released O-RAN specifications please read our web announcement. All O-RAN specifications are available for download at our website.
O-RAN Global PlugFest Spring 2023 Set to Start at Labs Across Asia, Europe, and North America
The first of the two O-RAN Global PlugFests planned for 2023 will be held in:
- South Korea hosted by KT
- Taiwan hosted by Auray Technology
- Europe hosted by Deutsche Telekom, EANTC, EURECOM, Orange, Telefónica and Vodafone
- USA hosted by University of New Hampshire InterOperability Laboratory
More than 55 companies have indicated their plan to participate.
Planned activities include interoperability and E2E testing, validation and demonstration of Radio Intelligent Controller (RIC) use cases, as well as X-haul transport, O-Cloud, QoS, and security testing.
F2F Meetings Boost Progress of O-RAN Technical Groups
With the easing of pandemic restrictions, O-RAN ALLIANCE resumed face-to-face meetings of its technical groups, greatly accelerating progress in specifications development. Latest F2F meetings took place in February 2023 in Prague with more than 430 delegates from 115 companies and institutions around the world. O-RAN plans to hold two more F2F meetings in 2023, one in June and one in October.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information, please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005917/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom